Gynecologic CancerFARGONCT05738252
Frailty Assessments for Risk Assessment in Gynecologic Oncology Patients
An observational study of Gynecologic Cancer and Frailty, run by Population Health Research Institute at 4 sites in Canada.
Trial summary
FARGO is a prospective cohort study that aims to determine the performance of preoperative frailty assessment based on the Frailty Phenotype (FP), compared to a perioperative cardiovascular risk assessment based on the combination of preoperative Revised Cardiac Risk Index (RCRI), age and occurrence of myocardial… Read more about this study
- Who is it for?
- Ages 55 to 110 years, women only
- Conditions the study is for
- Gynecologic Cancer, Frailty, Oncology
- What is being tested?
- Clinical Frailty Scale and Frailty Phenotype
- How many people
- 280 participants
- Where
- 4 sitesCanada
- Study dates
- 15 Jun 2023to Oct 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 to 110 years
- Women only
- No healthy volunteers
- Adult, Older adult
Study population: FARGO will recruit patients aged 55 or older, with confirmed or suspected gynecologic cancer, undergoing cytoreductive or high-risk surgery with or without chemotherapy.
Who may be able to join
- Age must be 55 years or older at registration
- Must meet any one of the following criteria:
- Have stage II-IV ovarian or endometrial cancer, undergoing cytoreductive surgery via laparotomy, with or without neoadjuvant chemotherapy (NACT)
- Have any stage endometrial, uterine or cervical cancer planned for laparotomy where laparoscopy is deemed unfeasible/high-risk due to comorbidities
- Are undergoing laparotomy for pelvic mass, highly suspicious for malignancy; or
- Are undergoing laparotomy for gynecologic malignancy recurrence.
Who cannot join
- Unable to provide informed consent
- Require urgent surgery within 24 hours of first consultation to the Gynecological Oncology team
- Are undergoing neoadjuvant radiation therapy
- Have a previously documented history of dementia
- Have cognitive, language, vision, or hearing impairment that impacts ability to understand the directions for the completion of the study instruments
- Are participating in a clinical trial investigating a new systemic therapy
Trial locations and contacts
4 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Canada4 sites, 4 recruiting
- Recruiting
Juravinksi Hospital
Hamilton, Ontario, L8V 1C3
Julie My Van Nguyen, MD, 905-521-2100, nguyenjmv@HHSC.CA
- Recruiting
Credit Valley Hospital
Mississauga, Ontario, L5M 2N1
Tiffany Zigras, MD
- Recruiting
Sunnybrook
Toronto, Ontario, M4N 3M5
Danielle Vicus, MD
- Recruiting
University Health Network
Toronto, Ontario, M5G 2Z5
Liat Hogen, MD, 416-946-4501 ext. 5065, Liat.Hogen@uhn.ca
About this study
Official title: Frailty Assessments for Risk Assessment in Gynecologic Oncology Patients Undergoing Surgery and Chemotherapy
FARGO is a prospective cohort study that aims to determine the performance of preoperative frailty assessment based on the Frailty Phenotype (FP), compared to a perioperative cardiovascular risk assessment based on the combination of preoperative Revised Cardiac Risk Index (RCRI), age and occurrence of myocardial injury after noncardiac surgery (MINS), in predicting the composite of all-cause death or new disability at 6 months after surgery in patients aged 55 or older. Patients will have confirmed or suspected gynecologic cancer, undergoing cytoreductive or high-risk surgery with or without chemotherapy.
Read the detailed description
Little is known about how to best predict postoperative outcomes, recovery from complications, and chemotherapy tolerance in an increasingly older and medically complex GO population. Measuring frailty may represent a comprehensive tool for risk prediction. The study 1) will help fill the current gap in knowledge; 2) will translate into clinical practice changes both locally, and when replicated in a larger multi-centre study, elsewhere in Canada and worldwide; and 3) will inform future studies on shared decision-making strategies and interventions.
By evaluating the role of frailty as a static or dynamic predictor of patient important outcomes, and by considering the complexity of these patients and also of their treatment trajectories, the study has the potential to fill those gaps and influence how care is delivered. By involving stakeholders in the evaluation of feasibility and acceptability of frailty assessment, this will inform a change in care that is sustainable, innovative, and patient-centred.
There have been substantial knowledge advancements about perioperative risk factors and the long-term impact of postoperative complications; however, oncology patients and patient-reported outcomes have been insufficiently studied. There is increased literature on frailty assessment in noncardiac surgery; however, studies that included GO patients are few and of low-quality. The study will overcome the limitations of the current knowledge and practice, and will potentially change healthcare delivery.
- Conditions
- Gynecologic Cancer, Frailty, Oncology
- Being tested
- Clinical Frailty Scale, Frailty Phenotype
- Medical subject headings
- Frailty, Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Clinical Frailty ScaleDiagnostic test
Also called CFS
A way to summarize the overall level of fitness or frailty of an older adult after they had been evaluated by an experienced clinician
Frailty PhenotypeDiagnostic test
Also called FP
Defined by the presence of three from the following five clinical features: weakness, slow walking speed, unintentional weight loss, exhaustion, and low physical activity
| Study group | Role | What they receive |
|---|---|---|
| Group A | We expect that some of the eligible patients (Group A) will undergo surgery without NACT. Group A will undergo only one preoperative study visit (baseline) within 45 days prior to their surgery. Group A will complete the study assessments and follow-ups. Some patients of Group A will undergo adjuvant chemotherapy after surgery; this will not affect their study timeline. Receives: Diagnostic Test: Clinical Frailty Scale; Diagnostic Test: Frailty Phenotype | |
| Group B | Patients undergoing NACT before their surgery (group B) will have a first baseline study assessment within 45 days prior to their first chemotherapy treatment; in this group, a second preoperative study visit will be repeated after chemotherapy is considered terminated at least 18 days post-chemotherapy cycle and within 45 days prior to surgery. Group B will complete the study assessments and follow-ups. Some patients of Group B will undergo adjuvant chemotherapy after surgery; this will not affect their study timeline. Receives: Diagnostic Test: Clinical Frailty Scale; Diagnostic Test: Frailty Phenotype | |
| Group C | Post-chemotherapy, a small proportion of patients will not be deemed eligible for surgery by the treating physician (group C). Group C will be included in the evaluation of chemotherapy-related outcomes, and will also be asked to complete a follow-up visit 6 months from the date of registration Receives: Diagnostic Test: Clinical Frailty Scale; Diagnostic Test: Frailty Phenotype | |
| Group D | An even smaller proportion of patients will initially be deemed eligible, recruited, and will complete the baseline assessment; however, they will eventually not undergo neither surgery nor chemotherapy. For Group D, a follow-up visit at 6 months from the baseline visit will be completed. Receives: Diagnostic Test: Clinical Frailty Scale; Diagnostic Test: Frailty Phenotype |
What is being measured
The primary outcome is the main question the study is designed to answer.
All-cause death or new disability at 6 months
Disability status is determined using the 12-item World Health Organization Disability Assessment Schedule (WHODAS 2.0). New disability at any time point is based according to the following criteria that account for baseline disability scores:
- For individuals with a disability score of <25% at baseline, new disability is defined as a disability score ≥25% at follow-up;
- For individuals with a disability score ≥25%, new disability is defined an increase in disability score of ≥8%.
Vascular death is defined as any death with a vascular cause and includes those deaths following a myocardial infarction, cardiac arrest, stroke, cardiac revascularization procedure (i.e., percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery), pulmonary embolus, hemorrhage, or deaths due to an unknown cause. Non-vascular death is defined as any death due to a clearly documented non-vascular cause (e.g. trauma, infection, malignancy).
Measured: 6 months
Secondary outcomes (17)
All cause death
Vascular death is defined as any death with a vascular cause and includes those deaths following a myocardial infarction, cardiac arrest, stroke, cardiac revascularization procedure (i.e., percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery), pulmonary embolus, hemorrhage, or deaths due to an unknown cause. Non-vascular death is defined as any death due to a clearly documented non-vascular cause (e.g., trauma, infection, malignancy).
Measured: 28 days and 1 year
Oncologic Outcomes: Progression Free Survival (PFS)
PFS, defined as the time from treatment initiation to tumor progression or recurrence or death from any cause, or to the date of censoring at the last time the subject was known to be alive. Cancer progression/recurrence will be defined as a measurable progression/recurrence documented on imaging.
Measured: at 6 and 12 months
Oncologic Outcomes: Cancer-specific death
Cancer-specific death is death directly attributable to the primary gynecological cancer or directly related to its treatment, in the absence of other causes of death.
Measured: at 6 and 12 months
New Disability
Disability status is determined using the 12-item World Health Organization Disability Assessment Schedule (WHODAS 2.0). New disability at any time point is based according to the following criteria that account for baseline disability scores:
- For individuals with a disability score of <25% at baseline, new disability is defined as a disability score ≥25% at follow-up;
- For individuals with a disability score ≥25%, new disability is defined an increase in disability score of ≥8%.
Definition of new disability at 28 days, 6 months, and 1 year after surgery will use as baseline disability score the WHODAS 2.0 score measured before surgery.
Measured: 28 days, 6 months and 1 year after surgery
Major vascular complications
defined as a composite of vascular death, and non-fatal myocardial infarction (or myocardial injury for the 28-day time point), stroke, symptomatic proximal venous thromboembolism, and cardiac arrest
Measured: at 28 days, 6 months, and 1 year after surgery
Infection, and infection with sepsis
Infection is defined as a pathologic process caused by the invasion of normally sterile tissue or fluid or body cavity by pathogenic or potentially pathogenic organisms.
The Third International Consensus Definitions Task Force defines sepsis as a "life-threatening organ dysfunction due to a dysregulated host response to infection." Based on the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) criteria, sepsis will require a quick Sequential Organ Failure Assessment (qSOFA) Score ≥2 points due to infection. The qSOFA includes the following items and scoring system:
- Altered mental status (1 point)
- systolic blood pressure of 100 mm Hg or less (1 point), and
- respiratory rate of 22 breaths/min or more (1 point).
Measured: at 28 days, 6 months, and 1 year after surgery
In-hospital delirium
Delirium during the first 3 days after surgery or before discharge from the hospital, based on Confusion Assessment Method (CAM). According to CAM, patients are diagnosed with delirium if they meet the first 2 criteria (acute onset with fluctuating course, AND attention deficit), and at least one of the second 2 criteria (disorganized thinking OR altered level of consciousness). Participants will be screened for postoperative delirium while in hospital, twice daily, during the first 3 days after surgery or until discharge (if before 3 days), by research personnel, using the 3D-CAM, or the CAM-ICU any time the participants are in the PACU or in ICU
Measured: During the index hospital admission for surgery up to the first 3 days after surgery or before discharge from hospital
Bleeding Independently Associated with Mortality after noncardiac Surgery
BIMS is a bleeding meeting any of the following 3 criteria:
- Leading to a postoperative hemoglobin <70 g/L
- Requiring transfusion of one or more units of red blood cells
- Judged to be the immediate cause of death
Measured: 28 days after surgery
Acute congestive heart failure
The definition of congestive heart failure requires at least one of the following clinical signs (i.e. any of the following signs: elevated jugular venous pressure, respiratory rales/crackles, crepitations, or presence of S3) and at least one of the following:
- Radiographic findings (i.e., vascular redistribution, interstitial pulmonary edema, or frank alveolar pulmonary edema) OR
- Heart failure treatment implemented with diuretics with documented clinical improvement.
Measured: 28 days after surgery, 6 months and 1 year after surgery
Unplanned admission to ICU
admission to the ICU that was not planned
Measured: during index hospitalization for surgery
New clinically important atrial fibrillation
The definition of new clinically important atrial fibrillation requires the documentation of atrial fibrillation or atrial flutter of any duration on an ECG or rhythm strip, which results in angina congestive heart failure, symptomatic hypotension, or requires treatment with a rate controlling drug, antiarrhythmic drug, or electrical cardioversion.
Measured: 28 days after surgery, 6 months and 1 year after surgery
Length of stay
time spent in hospital immediately after surgery
Measured: during index hospitalization for surgery
Chemotherapy-related outcomes: total dose received
This will be measured at the end of any chemotherapy treatment when considered terminated:
Total dose received, defined as Relative Dose Intensity (RDI), as calculated as the percentage of the standard dose that was administered
Measured: Before Surgery, 6-months post-surgery
Chemotherapy-related outcomes: time to completion of all chemotherapy cycles
This will be measured at the end of any chemotherapy treatment when considered terminated:
Time to completion of all chemotherapy cycles (number of days)
Measured: Before Surgery, 6-months post-surgery
Chemotherapy-related outcomes: patient's decisional regret
This will be measured at the end of any chemotherapy treatment when considered terminated:
Patient's decisional regret, defined as "distress or remorse after a (health care) decision," assessed using the Decisional Regret scale, a validated a 5-item scale
Measured: Before Surgery, 6-months post-surgery
Chemotherapy-related outcomes: Change in health-related function or well-being
This will be measured at the end of any chemotherapy treatment when considered terminated:
Change in health-related function or well-being, defined as the difference in WHODAS 2.0 score after chemotherapy compared to before chemotherapy.
Measured: Before Surgery, 6-months post-surgery
Chemotherapy-related outcomes
This will be measured at the end of any chemotherapy treatment when considered terminated:
Change in health-related quality of life, defined as the difference in FACT-G7 score after chemotherapy compared to before chemotherapy.
Measured: Before Surgery, 6-months post-surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Feb 2023
- Study start15 Jun 2023
- Primary completionMay 2025 (estimated)
- Study completionOct 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Gynecologic CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 280 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Population Health Research Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Maura Marcucci, MD, Principal investigator, Population Health Research Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05738252
- Sponsor's protocol ID
- v1.0_20211130
- Acronym
- FARGO
- Status last verified
- Apr 2025
- First submitted
- 31 Jan 2023
- Last updated
- 16 Apr 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Nguyen JMV, Vicus D, Hogen L, Zigras T, Pare G, Chong M, Benitez YR, Devereaux PJ, Ofori S, Borges FK, Di Sante E, Miletic D, Panus O, Vincent J, Ramasundarahettige C, Nene S, Patel A, Marcucci M. Frailty Assessment for Risk prediction in Gynecologic Oncology patients undergoing surgery and chemotherapy (FARGO) study protocol: Rationale and design of a multi-centre prospective cohort study. PLoS One. 2025 Jul 28;20(7):e0325651. doi: 10.1371/journal.pone.0325651. eCollection 2025.
PubMed 40720507
Study at a glance
From the registry record, last updated by the sponsor on 16 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Frailty Assessments for Risk Assessment in Gynecologic Oncology Patients Undergoing Surgery and Chemotherapy
- ClinicalTrials.gov ID
- NCT05738252
- Acronym / sponsor ID
- FARGO / v1.0_20211130
- Conditions
- Gynecologic Cancer, Frailty, Oncology
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 280 participants (estimated)
- Lead sponsor
- Population Health Research InstituteUniversity, hospital or other
- Study start
- 15 Jun 2023 (actual)
- Primary completion
- May 2025 (estimated)
- Study completion
- Oct 2025 (estimated)
- First posted
- 22 Feb 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
FARGO is a prospective cohort study that aims to determine the performance of preoperative frailty assessment based on the Frailty Phenotype (FP), compared to a perioperative cardiovascular risk assessment based on the combination of preoperative Revised Cardiac Risk Index (RCRI), age and occurrence of myocardial injury after noncardiac surgery (MINS), in predicting the composite of all-cause death or new disability at 6 months after surgery in patients aged 55 or older. Patients will have confirmed or suspected gynecologic cancer, undergoing cytoreductive or high-risk surgery with or without chemotherapy.
Detailed description
Little is known about how to best predict postoperative outcomes, recovery from complications, and chemotherapy tolerance in an increasingly older and medically complex GO population. Measuring frailty may represent a comprehensive tool for risk prediction. The study 1) will help fill the current gap in knowledge; 2) will translate into clinical practice changes both locally, and when replicated in a larger multi-centre study, elsewhere in Canada and worldwide; and 3) will inform future studies on shared decision-making strategies and interventions.
By evaluating the role of frailty as a static or dynamic predictor of patient important outcomes, and by considering the complexity of these patients and also of their treatment trajectories, the study has the potential to fill those gaps and influence how care is delivered. By involving stakeholders in the evaluation of feasibility and acceptability of frailty assessment, this will inform a change in care that is sustainable, innovative, and patient-centred.
There have been substantial knowledge advancements about perioperative risk factors and the long-term impact of postoperative complications; however, oncology patients and patient-reported outcomes have been insufficiently studied. There is increased literature on frailty assessment in noncardiac surgery; however, studies that included GO patients are few and of low-quality. The study will overcome the limitations of the current knowledge and practice, and will potentially change healthcare delivery.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Group A | – | Diagnostic Test: Clinical Frailty Scale, Diagnostic Test: Frailty PhenotypeWe expect that some of the eligible patients (Group A) will undergo surgery without NACT. Group A will undergo only one preoperative study visit (baseline) within 45 days prior to their surgery. Group A will complete the study assessments and follow-ups. Some patients of Group A will undergo adjuvant chemotherapy after surgery; this will not affect their study timeline. |
| Group B | – | Diagnostic Test: Clinical Frailty Scale, Diagnostic Test: Frailty PhenotypePatients undergoing NACT before their surgery (group B) will have a first baseline study assessment within 45 days prior to their first chemotherapy treatment; in this group, a second preoperative study visit will be repeated after chemotherapy is considered terminated at least 18 days post-chemotherapy cycle and within 45 days prior to surgery. Group B will complete the study assessments and follow-ups. Some patients of Group B will undergo adjuvant chemotherapy after surgery; this will not affect their study timeline. |
| Group C | – | Diagnostic Test: Clinical Frailty Scale, Diagnostic Test: Frailty PhenotypePost-chemotherapy, a small proportion of patients will not be deemed eligible for surgery by the treating physician (group C). Group C will be included in the evaluation of chemotherapy-related outcomes, and will also be asked to complete a follow-up visit 6 months from the date of registration |
| Group D | – | Diagnostic Test: Clinical Frailty Scale, Diagnostic Test: Frailty PhenotypeAn even smaller proportion of patients will initially be deemed eligible, recruited, and will complete the baseline assessment; however, they will eventually not undergo neither surgery nor chemotherapy. For Group D, a follow-up visit at 6 months from the baseline visit will be completed. |
Who may qualify
- Ages
- 55 to 110 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- FARGO will recruit patients aged 55 or older, with confirmed or suspected gynecologic cancer, undergoing cytoreductive or high-risk surgery with or without chemotherapy.
Key inclusion criteria (6 listed)
- Age must be 55 years or older at registration
- Must meet any one of the following criteria:
Key exclusion criteria (6 listed)
- Unable to provide informed consent
- Require urgent surgery within 24 hours of first consultation to the Gynecological Oncology team
- Are undergoing neoadjuvant radiation therapy
- Have a previously documented history of dementia
- Have cognitive, language, vision, or hearing impairment that impacts ability to understand the directions for the completion of the study instruments
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Clinical Frailty ScaleAlso: CFSA way to summarize the overall level of fitness or frailty of an older adult after they had been evaluated by an experienced clinician | Diagnostic test | Group A, Group B, Group C, Group D |
| Frailty PhenotypeAlso: FPDefined by the presence of three from the following five clinical features: weakness, slow walking speed, unintentional weight loss, exhaustion, and low physical activity | Diagnostic test | Group A, Group B, Group C, Group D |
Primary outcome
All-cause death or new disability at 6 months
Time frame: 6 months
Disability status is determined using the 12-item World Health Organization Disability Assessment Schedule (WHODAS 2.0). New disability at any time point is based according to the following criteria that account for baseline disability scores: 1. For individuals with a disability score of <25% at baseline, new disability is defined as a disability score ≥25% at follow-up; 2. For individuals with a disability score ≥25%, new disability is defined an increase in disability score of ≥8%. Vascular death is defined as any death with a vascular cause and includes those deaths following a myocardial infarction, cardiac arrest, stroke, cardiac revascularization procedure (i.e., percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery), pulmonary embolus, hemorrhage, or deaths due to an unknown cause. Non-vascular death is defined as any death due to a clearly documented non-vascular cause (e.g. trauma, infection, malignancy).
17 secondary outcomes
All cause death
Time frame: 28 days and 1 year
Oncologic Outcomes: Progression Free Survival (PFS)
Time frame: at 6 and 12 months
Oncologic Outcomes: Cancer-specific death
Time frame: at 6 and 12 months
New Disability
Time frame: 28 days, 6 months and 1 year after surgery
Major vascular complications
Time frame: at 28 days, 6 months, and 1 year after surgery
Infection, and infection with sepsis
Time frame: at 28 days, 6 months, and 1 year after surgery
In-hospital delirium
Time frame: During the index hospital admission for surgery up to the first 3 days after surgery or before discharge from hospital
Bleeding Independently Associated with Mortality after noncardiac Surgery
Time frame: 28 days after surgery
Acute congestive heart failure
Time frame: 28 days after surgery, 6 months and 1 year after surgery
Unplanned admission to ICU
Time frame: during index hospitalization for surgery
New clinically important atrial fibrillation
Time frame: 28 days after surgery, 6 months and 1 year after surgery
Length of stay
Time frame: during index hospitalization for surgery
Chemotherapy-related outcomes: total dose received
Time frame: Before Surgery, 6-months post-surgery
Chemotherapy-related outcomes: time to completion of all chemotherapy cycles
Time frame: Before Surgery, 6-months post-surgery
Chemotherapy-related outcomes: patient's decisional regret
Time frame: Before Surgery, 6-months post-surgery
Chemotherapy-related outcomes: Change in health-related function or well-being
Time frame: Before Surgery, 6-months post-surgery
Chemotherapy-related outcomes
Time frame: Before Surgery, 6-months post-surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Apr 2025.
- Derived from this study: PubMed 40720507Nguyen JMV, Vicus D, Hogen L, Zigras T, Pare G, Chong M, Benitez YR, Devereaux PJ, Ofori S, Borges FK, Di Sante E, Miletic D, Panus O, Vincent J, Ramasundarahettige C, Nene S, Patel A, Marcucci M. Frailty Assessment for Risk prediction in Gynecologic Oncology patients undergoing surgery and chemotherapy (FARGO) study protocol: Rationale and design of a multi-centre prospective cohort study. PLoS One. 2025 Jul 28;20(7):e0325651. doi: 10.1371/journal.pone.0325651. eCollection 2025.
Related trials for Gynecologic Cancer
RecruitingPhase 2
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm
Recruiting
INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study
Breast Cancer, Corpus Uteri Cancer
Not yet recruiting
Gut Microbiome in Patients With Lung and Melanoma Cancer and Intestinal Microbiota in Gynecologic Cancers
Non Small Cell Lung Cancer, Melanoma (Skin Cancer)
Enrolling by invitation
Peer Ambassador in Gyn Onc Trials
Ovarian Cancer
RecruitingObservational study
Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study
Malignant Digestive System Neoplasm, Malignant Female Reproductive System Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Maura Marcucci, MD principal investigator
Population Health Research Institute
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Gynecologic Cancer and Frailty, run by Population Health Research Institute at 4 sites in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Julie My Van Nguyen, MD (905-521-2100, nguyenjmv@HHSC.CA), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
All-cause death or new disability at 6 months (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05738252, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Apr 2025.